Repare Therapeutics Inc
NASDAQ:RPTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
CA |
|
EVRAZ plc
LSE:EVR
|
UK |
|
Global Energy Ventures Ltd
ASX:GEV
|
AU |
|
A
|
Aether Holdings Inc
NASDAQ:ATHR
|
US |
|
Guanfu Holdings Co Ltd
SZSE:002102
|
CN |
|
Rex International Holding Ltd
SGX:5WH
|
SG |
|
CITIC Securities Co Ltd
SSE:600030
|
CN |
|
Geberit AG
SIX:GEBN
|
CH |
|
Allovir Inc
NASDAQ:ALVR
|
US |
|
Guangdong Kitech New Material Holding Co Ltd
SZSE:300995
|
CN |
|
C
|
China Container Terminal Corp
TWSE:2613
|
TW |
|
AnAn International Ltd
SGX:Y35
|
SG |
|
MT Hoejgaard Holding A/S
CSE:MTHH
|
DK |
|
I
|
Invesco Ltd
XBER:3IW
|
US |
|
Instructure Holdings Inc
NYSE:INST
|
US |
|
H
|
Hera SpA
XBER:HE9
|
IT |
|
C
|
Cuscapi Berhad
KLSE:CUSCAPI
|
MY |
|
B
|
Blue Foundry Bancorp
NASDAQ:BLFY
|
US |
Repare Therapeutics Inc
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 152 full-time employees. The company went IPO on 2020-06-19. The firm is focused on the development of synthetic lethality (SL) based therapies to patients with cancer. The company uses genome wide, SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The firm is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related (ATR) protein kinase for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated (ATM) kinase gene. Its preclinical programs include RP-6306 Protein Kinase Membrane-associated tYrosine- and Threonine- specific cdc-2 inhibitory (PKMYT1)kinase SL inhibitor, in advanced solid tumors.
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 152 full-time employees. The company went IPO on 2020-06-19. The firm is focused on the development of synthetic lethality (SL) based therapies to patients with cancer. The company uses genome wide, SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The firm is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related (ATR) protein kinase for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated (ATM) kinase gene. Its preclinical programs include RP-6306 Protein Kinase Membrane-associated tYrosine- and Threonine- specific cdc-2 inhibitory (PKMYT1)kinase SL inhibitor, in advanced solid tumors.
